NurOwn® will be made available for ALS patients who completed all Phase 3 clinical trial assessments and meet specific eligibility criteria NEW YORK, Dec. 14, 2020 /PRNewswire/ -- BrainStorm Cell ...
A conference call and webcast will be held Tomorrow, April 9, at 8:00 a.m. Eastern Time NEW YORK, April 8, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of ...
This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. There’s bi-partisan support in North ...
NEW YORK, July 8, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, is hosting a Key Opinion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results